A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
Phase 2
18–65
2 sites in CA, KS
About this study
This Phase 2 study is focused on people with obesity. The primary outcome being measured is Part A - Number of treatment emergent adverse events (TEAEs).
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Part A - Number of treatment emergent adverse events (TEAEs), Part B - Relative change in body weight, Part C- AUC; the area under the UBT251 plasma concentration time curve
Secondary: Part A - AUC; the area under the UBT251 plasma concentration-time curve, Part A - Change in body weight, Part A - Cmax; the maximum plasma concentration of UBT251, Part A - Relative change in body weight, Part B - Change in body weight, Part B - Change in waist circumference, Part B - Number of TEAEs, Part C - Cmax; the maximum plasma concentration of UBT251
Endocrinology